Clinical response of quetiapine in rapid cycling manic bipolar patients and lactate level changes in proton magnetic resonance spectroscopy

Dajung J. Kim, In Kyoon Lyoo, Sujung J. Yoon, Taeyoung Choi, Byungchol Lee, Jieun E. Kim, Joonsun S. Lee, Perry F. Renshaw

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The aim of the current study was to evaluate the relationship between quetiapine's effect on the improvement of mood symptoms in bipolar patients and brain metabolite level changes as measured by proton magnetic resonance spectroscopy (1H-MRS). Rapid cycling bipolar patients in the manic state were recruited and treated with quetiapine for 12 weeks. Clinical assessment was performed using the Young Mania Rating Scale (YMRS), the 17-item Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression-Severity scale (CGI-S) at baseline and weekly intervals during the 12-week period. In order to evaluate metabolite level changes over time, 1H-MRS scans were acquired at baseline and week 12. There were significant reductions in YMRS scores (by 43.0%), HDRS scores (by 27.5%) and CGI-S score (by 44.6%) over the 12 week-period. Lactate levels significantly decreased over the 12-week study period (22.4%). This change in lactate levels was more prominent in quetiapine responders than in non-responders. Additionally, there was a positive correlation between changes in lactate levels and those in YMRS scores (r = 0.52, p = 0.003). Our findings suggest that quetiapine's antimanic and antidepressant efficacy in patients with rapid cycling bipolar disorder may potentially be related to decreased lactate levels in frontal regions of the brain.

Original languageEnglish
Pages (from-to)1182-1188
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Issue number6
StatePublished - 15 Aug 2007

Bibliographical note

Funding Information:
This study is supported in part by the Investigator-Initiated Trial of the AstraZeneca (I.K.L.) and Stanley Medical Research Institute (Lyoo IK, Renshaw PF), NARSAD Independent Investigator Award (Lyoo IK, Renshaw PF) and NIH RO1-MH058681 (Renshaw PF).


  • Bipolar disorder
  • Lactate
  • Magnetic resonance spectroscopy
  • Quetiapine


Dive into the research topics of 'Clinical response of quetiapine in rapid cycling manic bipolar patients and lactate level changes in proton magnetic resonance spectroscopy'. Together they form a unique fingerprint.

Cite this